Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents

Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several patents.